The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
| Image |  |
|---|---|
| Description | scientific article published on 15 May 2020 |
| Author/s |
author: Y Meng Rachael Batteson |
| Publication date | May 15, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |